https://www.cardiologiaambulatoriale.eu/osimertinib-induced-venous-thromboembolism-in-lung-cancer-a-challenging-clinical-case/

Venous thromboembolism is the second leading cause of mortality among cancer patients, with a 20% incidence, after the progression of cancer itself. In the last two years clinical trials have studied direct oral anticoagulants also in the oncological clinical setting with prom-ising results in efficacy and safety. Osimertinib has been approved for the treatment of EGFR T790M mutation-positive non small cell lung cancer resistant to first- and second-generation EGFR tirosin kinase inhibitors. However, little is known about venous thromboem-bolism induced by osimertinib. Here, we report the case of a woman with lung cancer treated by osimertinib who developed deep vein thrombosis of the common femoral right vein, successfully treated wih edoxaban. In conclusion, on one side deep vein thrombosis is a possible side effect of osimertinib, on the other side edoxaban is a new practical, effective and safe therapeutic option also in active cancer patients.